Your browser doesn't support javascript.
loading
Health Status in Patients with COPD According to GOLD 2017 Classification: Use of the COMCOLD Score in Routine Clinical Practice.
Figueira Gonçalves, Juan Marco; Martín Martínez, María Dolores; Pérez Méndez, Lina Inmaculada; García Bello, Miguel Ángel; Garcia-Talavera, Ignacio; Hernández, Sara García; Díaz Pérez, David; Bethencourt Martín, Natalia.
Afiliação
  • Figueira Gonçalves JM; a Hospital Universitario Nuestra Señora de la Candelaria , Santa Cruz de Tenerife , Spain.
  • Martín Martínez MD; a Hospital Universitario Nuestra Señora de la Candelaria , Santa Cruz de Tenerife , Spain.
  • Pérez Méndez LI; a Hospital Universitario Nuestra Señora de la Candelaria , Santa Cruz de Tenerife , Spain.
  • García Bello MÁ; a Hospital Universitario Nuestra Señora de la Candelaria , Santa Cruz de Tenerife , Spain.
  • Garcia-Talavera I; a Hospital Universitario Nuestra Señora de la Candelaria , Santa Cruz de Tenerife , Spain.
  • Hernández SG; a Hospital Universitario Nuestra Señora de la Candelaria , Santa Cruz de Tenerife , Spain.
  • Díaz Pérez D; a Hospital Universitario Nuestra Señora de la Candelaria , Santa Cruz de Tenerife , Spain.
  • Bethencourt Martín N; a Hospital Universitario Nuestra Señora de la Candelaria , Santa Cruz de Tenerife , Spain.
COPD ; 15(4): 326-333, 2018.
Article em En | MEDLINE | ID: mdl-30398916
The COMCOLD score was developed to quantify the impact of comorbidities on health status in patients with chronic obstructive pulmonary disease (COPD). The objective of this study is to evaluate the association between health status in outpatients with COPD according to COMCOLD score and the GOLD 2017 groups according to symptoms (B and D vs. A and C) and exacerbations (C and D vs. A and B). 439 patients were included. The average score was 2.4 ± 3. 48% of cases had a COMCOLD score >0. The most symptomatic patients (B and D vs. A and C) had a higher score: 3 ± 3.3 vs. 1.3 ± 2.1 (p < 0.001), in contrast with the groups with a higher risk of exacerbation (C and D vs. A and B) in which there was no significant difference: 3 ± 3.5 vs. 2.2 ± 3.0 (p = 0.055). The most symptomatic patients (B and D) showed a greater prevalence of depression, peripheral artery disease and heart disease with an adjusted OR of 3.04 [CI95%: 1.36; 6.86], 2.49 [CI95%: 1.17; 5.29], and 4.41 [CI95%: 2.50; 7.75], respectively. Moreover, no relationship was found between the comorbidities defined by the COMCOLD score and the GOLD 2017 groups with the greatest risk of exacerbation (C and D). The greatest effect on health status was found in those patients with COPD belonging to the most symptomatic groups (B and D), with depression, peripheral artery disease, and heart disease being the main comorbidities involved.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nível de Saúde / Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nível de Saúde / Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article